Taiwan's Foresee Pharmaceuticals Co. has announced that Bassem Elmankabadi, M.D. joins Foresee as a Senior Vice President (VP) of Clinical Development.

Dr Elmankabadi is a Board Certified Surgeon with over 17 years of clinical background and experience in the pharmaceutical industry, including multiple clinical leadership roles at Amgen, FibroGen, and Blade Therapeutics.

He had many years of experience leading multiple health agencies' face-to-face interactions and negotiations, resulting in an agreement on four Clinical Development Plans for Phase 2 and 3 clinical studies across several indications of Cudetaxestat (ATX inhibitor) and Pamrevlumab (CTGF inhibitor).

Prior to Blade, FibroGen, and Amgen, he was a surgeon, medical director, clinical instructor at UCLA in Los Angeles for the KRAS oncogene programme. He spent 5+ years working for a CRO on several Phase 2/3 studies in retinal diseases.